Luton, Bedfordshire, United Kingdom, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The proteomics market is experiencing robust growth driven by several key factors. One of the primary drivers is the increasing demand for personalized medicine, which is reshaping clinical practices and enabling tailored treatments. The use of proteomics in drug discovery and development is also expanding, with the growing emphasis on discovering new biomarkers for disease diagnosis and treatment, as well as optimizing drug efficacy and safety.
Access PDF Sample Report (Including Graphs, Charts & Figures) @ https://www.exactitudeconsultancy.com/reports/15066/proteomics-market#request-a-sample
Moreover, substantial investments from both government and private sectors are fueling innovation in proteomics technologies. Clinical trials and translational research are benefitting from proteomics' ability to deliver insights that accelerate the development of novel therapies. In particular, the development of biologics and biosimilars is heavily reliant on proteomic techniques to ensure product quality and effectiveness.
There is also an increasing focus on monoclonal antibodies and therapeutic proteins, with proteomics playing a critical role in the characterization and optimization of these biologic therapies. The advancements in protein quantification techniques, including mass spectrometry and other high-throughput methods, are improving the accuracy and efficiency of protein analysis, further contributing to market growth.
In addition, single-cell proteomics has emerged as a significant area of interest, offering new insights into cellular functions and disease mechanisms at an unprecedented resolution. Coupled with the growth of bioinformatics, these advancements are driving innovation and providing deeper insights into complex biological systems.
The proteomics market is expected to reach a market value of $30 billion by 2026, with a compound annual growth rate (CAGR) of approximately 10%, driven by these factors and the ongoing expansion of applications across various sectors, from diagnostics to therapeutic development.
Proteomics Market Dynamics
Driver: Rising Demand for Personalized Medicine
The proteomics market is significantly benefiting from the growing demand for personalized medicine, which enables treatments tailored to individual patients. By providing deep molecular insights, proteomics allows for the discovery of biomarkers, identification of drug targets, and tracking of therapeutic responses, all of which support the development of targeted therapies. Over the past decade, personalized medicine has gained tremendous traction, with FDA approvals reflecting the increasing market need. For instance, in 2021, the FDA's Center for Drug Evaluation and Research approved 50 new molecular entities (NMEs), primarily focusing on therapeutic products. In 2022, 37 NMEs were approved, further showcasing the ongoing expansion in this domain. As personalized medicine continues to advance, proteomics is poised to play an even more significant role in the healthcare landscape, driving the need for more sophisticated analytical technologies.
Restraints: High Cost of Instruments
A major challenge in the growth of the proteomics market is the high initial investment required for advanced proteomics instruments. These tools, such as mass spectrometers and chromatography systems, are sophisticated, fully automated, and come with significant capital expenditures. For instance, the cost of state-of-the-art mass spectrometers can exceed USD 500,000. Additional expenses, including reagents for a single mass spectrometry analysis (which can cost between USD 100 to 300) and the ongoing training and hiring of specialists, can significantly increase operational costs. For smaller research labs or academic institutions, these high costs make it challenging to adopt these essential technologies, limiting their access to critical proteomics capabilities. Furthermore, the adoption of such advanced systems is particularly difficult for small and medium-sized enterprises (SMEs) in the biotech industry, despite their importance in regulatory compliance and product quality.
Opportunity: Advancements in Bioinformatics
The proteomics market is being driven by advancements in bioinformatics, particularly through the development of powerful software tools for data analysis and interpretation. Tools like MaxQuant and Proteome Discoverer are enhancing the efficiency of identifying and quantifying proteins, significantly improving both accuracy and speed. Additionally, next-generation sequencing (NGS) technologies are transforming the landscape of proteomics, offering rapid, cost-effective sequencing that reveals deviations in gene expression and helps to identify new therapeutic targets. Machine learning and artificial intelligence (AI) are further augmenting bioinformatics, especially in areas like protein structure prediction and drug target discovery. AI-powered algorithms, such as AlphaFold by DeepMind, are revolutionizing protein research by predicting protein structures with unprecedented precision. As these technologies evolve, they promise to accelerate the development of more effective therapies and drug candidates.
Challenge: Data Management and Handling in Proteomics Research
A significant challenge facing the proteomics market is the lack of efficient data management systems. While large volumes of proteomics data are being generated, the ability to access, organize, and analyze this data remains limited. Poor data management can severely hinder research outcomes and delay the discovery of biomarkers or the development of new drugs. Inefficiencies in handling high-throughput proteomics data often lead to delays in translating findings into actionable results, lengthening the product development cycle. Additionally, the lack of standardization across data formats and the difficulty of integrating data from different platforms or research initiatives complicate the process even further. Researchers spend significant time on data preprocessing and analysis, which detracts from more innovative activities. The absence of standardized repositories for proteomics data exacerbates these challenges, making it difficult for scientists to perform efficient and reproducible research.
Market Segment Analysis of the Proteomics Industry
Spectroscopy Dominates the Proteomics Market
In 2023, the spectroscopy segment emerged as the dominant force in the global proteomics market and is expected to maintain this position throughout the forecast period. This is primarily attributed to the increasing adoption of spectroscopy techniques, which are indispensable for understanding crucial aspects of protein research, including protein structure, dynamics, interactions, and functions. The ability of spectroscopy to provide detailed molecular-level insights has made it a preferred method for proteomics studies, driving sustained growth in this segment. Technologies such as infrared (IR) spectroscopy, Raman spectroscopy, and fluorescence spectroscopy are widely used to analyze proteins' chemical properties and behaviors, contributing to the overall market expansion.
Get a Free Sample copy (PDF):
https://www.exactitudeconsultancy.com/reports/15066/proteomics-market#request-a-sample
Immunoassay Reagents Set to Experience Significant Growth
Another promising segment within the proteomics industry is immunoassay reagents, which are projected to see substantial growth at a significant compound annual growth rate (CAGR) over the forecast period. The growing demand for reliable, specific, and rapid disease detection, particularly for early-stage diagnosis, is expected to propel the market for immunoassay reagents. This segment includes a broad range of reagents used in assays to detect biomarkers and track the progress of diseases such as cancer and autoimmune disorders. The versatility and effectiveness of these reagents in diagnosing a wide variety of diseases are major factors contributing to their rising demand in proteomics applications.
Regional Market Overview: North America Leads the Market
In 2023, North America emerged as the leader in the global proteomics market and is anticipated to maintain its dominance throughout the forecast period. The region’s leadership is driven by the presence of a large number of pharmaceutical and biotechnology companies, a robust research and development (R&D) ecosystem, and significant funding for precision medicine initiatives. North America’s market growth is also supported by increasing investments in the development of targeted therapies and biologics, alongside growing demand for personalized medicine solutions. The U.S., in particular, is a major contributor to this growth, owing to its well-established healthcare infrastructure and ongoing innovations in drug discovery and development.
Additionally, government and private research funding in North America continues to rise, further fueling market growth in the region. For example, the National Institutes of Health (NIH) and other agencies have been significantly increasing their support for proteomics research, which is likely to continue driving innovation and expanding the market for proteomics technologies. As a result, North America is expected to remain the largest and fastest-growing market for proteomics over the next several years.
Key Players:
- Waters Corporation
- Bio-Rad Laboratories, Inc.
- Bruker Corporation
- Agilent Technologies, Inc.
- Merck KGaA
- Revvity
- Shimadzu Corporation
- Illumina Inc.
- Promega Corporation
- Eurofins
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- QIAGEN
- Charles River Laboratories
- Protagene
Market Segmentations:
By Instrumentation Technology
- Spectroscopy
- Chromatography
- Chromatography
- Electrophoresis
- Protein Microarrays
- X Ray Crystallography
- Surface Plasmon Resonance
- Protein Fractionation
- Other Technologies
By Reagent
- Immunoassay Reagents
- Spectroscopy Reagents
- Chromatography Reagents
- Protein Microarray Reagents
- X Ray Crystallography Reagents
- Electrophoresis Reagents
- Protein Fractionation Reagents
- Other Reagents
By Service
- Core Proteomics Services
- Bioinformatics Services
By Software
- Bioinformatics Tools
- Bioinformatics Databases
By Applications
- Clinical Diagnostics
- Drug Discovery & Development
- Other Applications
By End User
- Hospitals
- Clinical Laboratories
- Biopharmaceutical Companies
- Academic & Research Institutes
- Other End Users
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments of Proteomics Industry
- In March 2024, Thermo Fisher Scientific introduced the Thermo Scientific Stellar mass spectrometer (MS), designed for fast throughput and high sensitivity. This innovation supports researchers in advancing their translational omics research by enabling more efficient and accurate breakthrough discoveries.
- In October 2023, Thermo Fisher Scientific acquired Olink Holdings, a leader in protein biomarker discovery, to enhance its capabilities in the rapidly growing proteomics market. This acquisition will solidify Thermo Fisher’s leadership in this sector.
- Agilent Technologies launched two major products in June 2024 at the 72nd ASMS Conference: the Agilent 7010D Triple Quadrupole GC/MS System and the Agilent ExD Cell for the 6545XT AdvanceBio LC/Q-TOF system. These innovations are set to drive advancements in both gas chromatography-mass spectrometry (GC/MS) and LC/Q-TOF technologies.
- In June 2024, Danaher Corporation collaborated with Mass Analytica to unveil artificial intelligence (AI) quantification software. This new software leverages AI for high-resolution MS/MS analysis, facilitating more precise proteomics research.
- SomaLogic launched the SomaScan 11K platform in November 2023, expanding its protein analysis capacity from 7,000 to 11,000 analytes. This increase significantly enhances biomarker discovery and supports precision medicine development.
- Olink introduced the Explore HT platform in July 2023, greatly expanding its ability to measure over 5,300 proteins, doubling its previous capacity. Additionally, the company is set to be acquired by Thermo Fisher for $3.1 billion, a move that will further strengthen its position in the proteomics industry.
This report is also available in the following languages: Japanese (プロテオミクス市場), Korea (단백질체학 시장), china (蛋白质组学市场), French (Marché de la protéomique), German (Proteomik-Markt), and Italy (Mercato della proteomica), etc.
Get a Sample PDF Brochure:
https://www.exactitudeconsultancy.com/reports/15066/proteomics-market#request-a-sample
More Related Reports:
Lab-on-a-Chip Device Market
https://www.exactitudeconsultancy.com/reports/35237/lab-on-a-chip-device-market
The global Lab-on-a-Chip Device Market size is projected to grow from USD 6.81 billion in 2023 to USD 14.14 billion by 2030, exhibiting a CAGR of 11% during the forecast period.
molecular Weight Marker Market
https://www.exactitudeconsultancy.com/reports/30466/molecular-weight-marker-market
The molecular weight marker market is expected to grow at 12.1% CAGR from 2023 To 2030. It was valued 422 million in 2023. It is expected to reach above USD 938.76 million by 2030.
Mass Spectrometry Market
https://www.exactitudeconsultancy.com/reports/28915/mass-spectrometry-market
The mass spectrometry market is expected to grow at 8.0 % CAGR from 2022 to 2029. It is expected to reach above USD 11.59 billion by 2029 from USD 5.8 billion in 2020.
Bioinformatics Cloud Platform Market
https://www.exactitudeconsultancy.com/reports/24459/bioinformatics-cloud-platform-market
The bioinformatics cloud platform market is expected to grow at 13.2% CAGR from 2022 to 2029. It is expected to reach above USD 7.39 billion by 2029 from USD 2.42 billion in 2020.
Cancer/Tumour Profiling Market
https://www.exactitudeconsultancy.com/reports/11006/cancer-tumour-profiling-market
Cancer/tumour profiling market size was valued at USD 8.37 billion in 2020 and is projected to reach USD 21.41 billion by 2029, growing at a CAGR of 11% from 2022 to 2029.
Bioinformatics Market
https://www.exactitudeconsultancy.com/reports/6395/bioinformatics-market
The global Bioinformatics market is anticipated to grow from USD 11.61 Billion in 2023 to USD 30.88 Billion by 2030, at a CAGR of 15 % during the forecast period.
Early Cancer Detection Market
https://www.exactitudeconsultancy.com/reports/1092/early-cancer-detection-market
The Global Early Cancer Detection Market is expected to grow at more than 13.8% CAGR from 2019 to 2028. It is expected to reach above USD 2,650 million by 2028 from a little above USD 909 million in 2019.
Metabolomics Market
https://www.exactitudeconsultancy.com/reports/30429/metabolomics-market
The global metabolomics market is expected to grow at 14% CAGR from 2023 to 2030. It is expected to reach above USD 7.13 billion by 2030 from USD 2.9 billion in 2023.
Bioinformatics Services Market
https://www.exactitudeconsultancy.com/reports/6433/bioinformatics-services-market
Bioinformatics Services Market size was valued at USD 2.3 billion in 2020 and is projected to reach USD 8.47 billion by 2029, growing at a CAGR of 15.6% from 2022 to 2029.
Glycomics and Glycobiology Market
https://www.exactitudeconsultancy.com/reports/23647/glycomics-or-glycobiology-market
The global Glycomics and Glycobiology market is expected to grow at a 16.8% CAGR from 2022 to 2029, from USD 5.54 Billion in 2029.
